Microneedle device for transport of molecules across tissue

Details Microneedle device for transport of molecules across tissue Microneedle device for transport of molecules across tissue

1998-06-10

2003-01-07

Nguyen, Anhtuan T. (Department: 3763)

Surgery

Means for introducing or removing material from body for...

Treating material introduced into or removed from body...

C604S191000

Reexamination Certificate

active

06503231

ABSTRACT:

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
Not applicable.
BACKGROUND OF THE INVENTION
This invention is generally in the field of devices for the transport of therapeutic or biological molecules across tissue barriers, such as for drug delivery.
Numerous drugs and therapeutic agents have been developed in the battle against disease and illness. However, a frequent limitation of these drugs is their delivery: how to transport drugs across biological barriers in the body (e.g., the skin, the oral mucosa, the blood-brain barrier), which normally do not transport drugs at rates that are therapeutically useful.
Drugs are commonly administered orally as pills or capsules. However, many drugs cannot be effectively delivered in this manner, due to degradation in the gastrointestinal tract and/or elimination by the liver. Moreover, some drugs cannot effectively diffuse across the intestinal mucosa. Patient compliance may also be a problem, for example, in therapies requiring that pills be taken at particular intervals over a prolonged time.
Another common technique for delivering drugs across a biological barrier is the use of a needle, such as those used with standard syringes or catheters, to transport drugs across (through) the skin. While effective for this purpose, needles generally cause pain; local damage to the skin at the site of insertion; bleeding, which increases the risk of disease transmission; and a wound sufficiently large to be a site of infection. The withdrawal of bodily fluids, such as for diagnostic purposes, using a conventional needle has these same disadvantages. Needle techniques also generally require administration by one trained in its use. The needle technique also is undesirable for long term, controlled continuous drug delivery.
Similarly, current methods of sampling biological fluids are invasive and suffer from the same disadvantages. For example, needles are not preferred for frequent routine use, such as sampling of a diabetic's blood glucose or delivery of insulin, due to the vascular damage caused by repeated punctures. No alternative methodologies are currently in use. Proposed alternatives to the needle require the use of lasers or heat to create a hole in the skin, which is inconvenient, expensive, or undesirable for repeated use.
An alternative delivery technique is the transdermal patch, which usually relies on diffusion of the drug across the skin. However, this method is not useful for many drugs, due to the poor permeability (i.e. effective barrier properties) of the skin. The rate of diffusion depends in part on the size and hydrophilicity of the drug molecules and the concentration gradient across the stratum corneum. Few drugs have the necessary physiochemical properties to be effectively delivered through the skin by passive diffusion. Iontophoresis, electroporation, ultrasound, and heat (so-called active systems) have been used in an attempt to improve the rate of delivery. While providing varying degrees of enhancement, these techniques are not suitable for all types of drugs, failing to provide the desired level of delivery. In some cases, they are also painful and inconvenient or impractical for continuous controlled drug delivery over a period of hours or days. Attempts have been made to design alternative devices for active transfer of drugs, or analyte to be measured, through the skin.
For example, WO 96/37256 by Silicon Microdevices, Inc. (Godshall) discloses a transdermal drug delivery apparatus that includes a cutter portion having a plurality of microprotrusions, which have straight sidewalls, extending from a substrate that is in communication with a drug reservoir. In operation, the microprotrusions penetrate the skin until limited by a stop region of the substrate and then are moved parallel to the skin to create incisions. Because the microprotrusions are dragged across the skin, the device creates a wound sufficiently large to be a site of infection. Channels in the substrate adjacent to the microprotrusions allow drug from the reservoir to flow to the skin near the area disrupted by the microprotrusions.
U.S. Pat. No. 5,250,023 to Lee et al. discloses a transdermal drug delivery device, which includes a plurality of skin needles having a diameter in the range of 50 to 400 &mgr;m. The skin needles are supported in a water-swellable polymer substrate through which a drug solution permeates to contact the surface of the skin. An electric current is applied to the device to open the pathways created by the skin needles, following their withdrawal from the skin upon swelling of the polymer substrate.
WO 93/17754 by Gross et al. discloses another transdermal drug delivery device that includes a housing having a liquid drug reservoir and a plurality of tubular elements for transporting liquid drug into the skin. The tubular elements may be in the form of hollow needles having inner diameters of less than 1 mm and an outer diameter of 1.0 mm.
While each of these devices has potential use, there remains a need for better drug delivery devices, which make smaller incisions, deliver drug with greater efficiency (greater drug delivery per quantity applied) and less variability of drug administration, and/or are easier to use.
It is therefore an object of the present invention to provide a microneedle device for relatively painless, controlled, safe, convenient transdermal delivery of a variety of drugs.
It is another object of the present invention to provide a microneedle device for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner.
SUMMARY OF THE INVENTION
Microneedle devices for transport of therapeutic and biological molecules across tissue barriers, and methods for manufacturing the devices, are provided. The microneedles have diameters between about 10 nm and 1 mm, and preferably are hollow or porous. The microneedle devices permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.
Microfabrication techniques are used to cost-effectively produce arrays of microneedles from metals, silicon, and polymeric materials. Methods are provided for making porous or hollow microneedles.
For transdermal drug delivery applications, the depth of penetration of the microneedles preferably is in the range of between about 10 &mgr;/m and 100 &mgr;m, so as to penetrate the stratum corneum barrier without penetrating into the dermis, thereby avoiding pain or bleeding, and the diameter of transport pathways created in the skin are preferably less than about 1 &mgr;m, to avoid making a hole which would allow bacteria to enter the penetration wound. The microneedles are also useful for minimally invasive diagnosis of biological fluids. A preferred embodiment of such biosensors is for use in monitoring blood glucose levels, as well as delivery of therapeutics such as insulin.


REFERENCES:
patent: 2893392 (1959-07-01), Wagner et al.
patent: 3034507 (1962-05-01), McConnell et al.
patent: 3086530 (1963-04-01), Groom
patent: 3123212 (1964-03-01), Taylor et al.
patent: 3136314 (1964-06-01), Kravitz
patent: RE25637 (1964-09-01), Kravitz et al.
patent: 3221739 (1965-12-01), Rosenthal
patent: 3221740 (1965-12-01), Rosenthal
patent: 3556080 (1971-01-01), Hein
patent: 3596660 (1971-08-01), Melone
patent: 3675766 (1972-07-01), Rosenthal
patent: 3918449 (1975-11-01), Pistor
patent: 3964482 (1976-06-01), Gerstel et al.
patent: 4109655 (1978-08-01), Chacornac
patent: 4159659 (1979-07-01), Nightingale
patent: 4222392 (1980-09-01), Brennan
patent: 4771660 (1988-09-01), Yacowitz
patent: 4798582 (1989-01-01), Sarath et al.
patent: 4921475 (1990-05-01), Sibalis
patent: 4969468 (1990-11-01), Byers et al.
patent: 5054339 (1991-10-01), Yacowitz
patent: 5138220 (1992-08-01), Kirkpatrick et al.
patent: 5250023 (1993-10-01), Lee et al.
patent: 5279544 (1994-01-01), Gross et al.
patent: 5279552 (1994-01-01), Magnet
patent: 5335670 (1994-08-01), Fishman
patent: 5364374 (1994-11-01), Morrison et al.

Affiliated with

Also associated with

Rating

Microneedle device for transport of molecules across tissue does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Microneedle device for transport of molecules across tissue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microneedle device for transport of molecules across tissue will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3049465